I-Mab Biopharma logo

I-Mab Biopharma

I-Mab Biopharma was established through a merger of Third Venture Biopharma and Tasgen in 2017, aiming to develop innovative biologics in the areas of immuno-oncology and autoimmune disease for the global markets, including China.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.i-mabbiopharma.com
Founded2017
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District,201210
Shanghai
China
Email
Contact Number
+86-21-6057 8000

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/i-mab” connections=”true” suffix=””]

In July 2018, I-Mab Biopharma out-license to ABL Bio, the global rights excluding Greater China to I-Mabs bispecific antibodies (BsAb) of undisclosed target with licensing payments of approx. US$100 Mn in total, with US$2.5 Mn in upfront payment. Also the two companies agreed to co-develop three novel Immuno-oncology (I-O) BsAbs utilizing ABL Bios innovative BsAb platform. The companies will share the development costs as well as rights in China, South Korea and rest of the world in different configurations.

In Dec 2017, I-Mab receives exclusive development and commercialization rights of HyLeukin for China, China Taiwan, Hong Kong and Macao from Genexine, Inc. HyLeukin is an immuno-oncology agent comprised of an optimally engineered Interleukin- 7 (IL-7) molecule based on Genexines proprietary long-acting protein platform technology, focusing on cancer, infectious diseases and lymphopenia.

In Dec 2017, I-Mab signed an exclusive regional licensing agreement with MorphoSys AG to develop and commercialize MOR202 in China, Taiwan, Hong Kong and Macao. MOR202 is MorphoSyss proprietary investigational antibody against CD38, for which recruitment of a European Phase 1/2a clinical study in relapsed/refractory multiple myeloma has been concluded.

In June 2018, I-Mab Biopharma, raised $220 Mn USD in Series C financing led by Hony Capital, with participations from Hillhouse Capital, HOPU Investments, CDH Investment, Ally Bridge Group, Singapore-based EDBI, and existing investors C-Bridge Capital and Tasly Capital.

In May 2017, I-Mab Biopharma raised $150 Mn in Series B financing. Key inestors includes C-Bridge/I-Bridge Capital, Management team, Genexine, Tasly Pharmaceuticals, Simcere Pharmaceuticals, TigerMed, Partners Investment, Qianhai Capital, Anlong Capital etc.